These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 15673596)

  • 1. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
    Tang C; Lin JH; Lu AY
    Drug Metab Dispos; 2005 May; 33(5):603-13. PubMed ID: 15673596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure in drug development: the role of inhibition and induction of cytochrome P450 enzymes.
    Hengstler JG; Bolt HM
    Arch Toxicol; 2008 Oct; 82(10):665-6. PubMed ID: 18751968
    [No Abstract]   [Full Text] [Related]  

  • 5. Updates on cytochrome P450-mediated cardiovascular drug interactions.
    Cheng JW; Frishman WH; Aronow WS
    Am J Ther; 2009; 16(2):155-63. PubMed ID: 19114873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.
    Chu V; Einolf HJ; Evers R; Kumar G; Moore D; Ripp S; Silva J; Sinha V; Sinz M; Skerjanec A
    Drug Metab Dispos; 2009 Jul; 37(7):1339-54. PubMed ID: 19389860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
    Muruganandan S; Sinal CJ
    Clin Pharmacol Ther; 2008 Jun; 83(6):818-28. PubMed ID: 18388875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions.
    Lee MD; Ayanoglu E; Gong L
    Xenobiotica; 2006; 36(10-11):1013-80. PubMed ID: 17118918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].
    Quiñones S L; Rosero P M; Roco A A; Moreno T I; Sasso A J; Varela F N; Cáceres L D; Saavedra S I
    Rev Med Chil; 2008 Oct; 136(10):1327-35. PubMed ID: 19194632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of drug metabolism: species differences and toxicological relevance.
    Graham MJ; Lake BG
    Toxicology; 2008 Dec; 254(3):184-91. PubMed ID: 18824059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic factors in drug metabolism.
    Belle DJ; Singh H
    Am Fam Physician; 2008 Jun; 77(11):1553-60. PubMed ID: 18581835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.
    Bjornsson TD; Callaghan JT; Einolf HJ; Fischer V; Gan L; Grimm S; Kao J; King SP; Miwa G; Ni L; Kumar G; McLeod J; Obach SR; Roberts S; Roe A; Shah A; Snikeris F; Sullivan JT; Tweedie D; Vega JM; Walsh J; Wrighton SA;
    J Clin Pharmacol; 2003 May; 43(5):443-69. PubMed ID: 12751267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
    Kanebratt KP; Andersson TB
    Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug essentials. The cytochrome P450 microenzyme system and targeted therapies: Minimizing drug interactions.
    Wilkes GM
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl Nurse Ed):33, 52-6. PubMed ID: 19856586
    [No Abstract]   [Full Text] [Related]  

  • 16. Interindividual variability in inhibition and induction of cytochrome P450 enzymes.
    Lin JH; Lu AY
    Annu Rev Pharmacol Toxicol; 2001; 41():535-67. PubMed ID: 11264468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Induction and repression of cytochromes P450. In vivo and in vitro approach].
    Batt AM; Strazielle N; Siegst G
    Therapie; 1993; 48(6):527-36. PubMed ID: 8091339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
    Foti RS; Wahlstrom JL
    IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs.
    Imai H; Kotegawa T; Ohashi K
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):409-11. PubMed ID: 22114850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.